Please amend the following claims under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

2. (Four times Amended) Purified FADD protein comprising the amino acid sequence shown in SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions produced by contacting a sample suspected of containing the FADD protein or polypeptide with a protein or polypeptide comprising the cytoplasmic domain of Fas under conditions suitable for the Fas-containing protein or polypeptide to bind the FADD protein or polypeptide to form a complex, and isolating any Fas-FADD complex formed, wherein the purified FADD protein has an apparent molecular weight of about 23.3 kDa as determined by an SDS polyacrylamide gel under reducing conditions.

3. (Four times Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 24 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

37. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 41 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of the Fas receptor.

38. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 111 to amino acid 180 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of the Fas receptor.

39. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 35 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

40. (Thrice Amended) A polypeptide fragment of claim 5, comprising amino acid 1 to amino acid 117 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog induces apoptosis in a suitable cell.

41. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 41 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

42. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 61 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

43. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 80 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

45. (Thrice Amended) A FADD mutein [protein] comprising the amino acid sequence shown in SEQ ID NO:2 and having asparagine at amino acid 121, or an analog thereof having conservative amino acid substitutions at amino acids 1 to 120 and 122 to 208, and the mutein or analog induces apoptosis in a suitable cell.

57. (Amended) A method for screening for an agent of claim 29 or 30, further comprising the step of analyzing the results of step b) to determine how the agent modulates apoptosis [the cellular function regulated by the Fas receptor pathway].

58. (Amended) A method for screening for an agent useful to modulate a cellular function regulated by FADD, the method comprising the steps of: